Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05651789

Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding

Conditions: Portal Hypertension, Varice Bleed, Cirrhosis, Liver

Sex: All
Ages: 18 Years – 80 Years
Phase: NA
Enrollment: 160
Sponsor: West China Hospital

Summary

This randomized controlled trial was conducted to evaluate the efficacy and safety of carvedilol versus propranolol, combined with routine endoscopic treatment, in the secondary prophylaxis of variceal bleeding in patients with cirrhosis.

Eligibility Criteria

Inclusion Criteria:Between 18 and 80 years old;With liver cirrhosis diagnosed by previous biopsy or by clinical criteria, and analytical image;At least 5 days after index variceal bleeding;Informed consent.Exclusion Criteria:Refusal to participate in the study;Portal hypertension resulting from other causes than liver cirrhosis;More than 42 days after index variceal bleeding;Bleeding from cardiofundal gastric varices;Portal venous thrombosis >50% of the portal vein trunk;Contraindications to beta-blockers (asthma, chronic obstructive pulmonary disease, atrioventricular block, heart failure, bradycardia with HR ≤40 bpm, arteria hypotension with systolic blood pressure <90 mm Hg, peripheral arterial disease, uncontrolled diabetes);Prior NSBB+EVL combined treatment, TIPS implantation or surgical shunt as secondary prophylaxis of variceal bledding;Chronic kidney disease;Pregnancy or lactation;Neoplastic disease.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05651789). StuddyBuddy aggregates publicly available trial information.